DOCSLIB.ORG

General Agreement on Tariffs Andtrade

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

GENERAL AGREEMENT ON RESTRICTED TAR/W/87 21 June 1993 TARIFFS AND TRADE Limited Distribution Committee on Tariff Concessions HARMONIZED COMMODITY DESCRIPTION AND CODING SYSTEM (Harmonized System) Classification of INN Substances The following communication has been received from the Nomenclature and Classification Directorate of the Customs Co-operation Council in Brussels. I am sending you herewith a list of the classification decisions of the INN substances which were taken at the 11th Session of the Harmonized System Committee held in Brussels in April 1993. I would also like to inform you that the classification of clobenoside and meclofenoxate will be discussed at the forthcoming meeting of the Scientific Sub-Committee early next year. The list of INN substances reproduced hereafter is available only in English. 93-1005 TAR/W/87 Page 2 Classification of INN Substances Agreed by the Harmonized System Committee in April 1993 Description HS Code 1 Acarbose 2932.90 2 Acemannan 3913.90 3 Aciclovir 2933.59 4 Acipimox 2933.90 5 Acitretin 2918.90 6 Aclantate 1934.90 7 Acrisorcin 2933.90 8 Acrivastine 2933.39 9 Acrocinonide 2937.22 10 Adibendan 2933.79 11 Alclofenac 2918.90 12 Aldesleukin 3504.00 13 Alfacalcidol 2936.10 14 Alfentanil 2933.39 15 Allopurinol 2933.59 16 Almagate 2842.90 17 Aloxistatin 2924.29 18 Alpertine 2933.59 19 Altapizone 2933.39 20 Altizide 2935.00 21 Ambasilide 2933.39 22 Ambruticin 2941.90 23 Amcinafal 2937.22 24 Amcinafide 2937.22 25 Amcinonide 2937.22 26 Amebucort 2937.29 27 Amfomycin 2941.90 28 Aminoethyl nitrate 2922.50 29 Amopyroquine 2933.40 30 Amphenidone 2933.79 31 Amylmetacresol 2907.19 32 Anagestone 2937.92 33 Anaritide 2934.90 34 Anaxirone 2934.90 35 Anazocine 2933.39 36 Ancrod 3507.90 37 Angiotensinamide 2933.29 38 Anistreplase 3507.90 39 Antazonite 2934.10 40 Aptazapine 2933.59 41 Arbekacin 2941.90 42 Arfalasin 2933.29 43 Arginine 2925.20 44 Arnolol 2922.19 45 Arotinolol 2934.10 46 Arprinocid 2933.59 TAR/W/87 Page 3 Description HS Code 47 Asobamast 2934.10 48 Astemizole 2933.39 49 Atamestane 2937.99 50 Atiprosin 2933.59 51 Atrimustine 2922.50 52 Atromepine 2939.90 53 Azabon 2935.00 54 Azatadine 2933.39 55 Azathioprine 2933.59 56 Azetirelin 2937.99 57 Benfurodil hemisuccinate 2932.29 58 Benolizime 2933.90 59 Benperidol 2933.39 60 Bentemazole 2933.z9 61 Benzindopyrine 2933.39 62 Benzopyrrcnium bromide 2933.90 63 Betiatide 2930.90 64 Bezafibrate 2924.29 65 Binfloxacin 2933.40 66 Binizolast 2933.59 67 Bisaramil 2933.39 68 Brazergoline 2939.60 69 Bremazocine 2933.39 70 Brifentanil 2933.39 71 Bromerguride 2939.60 72 Bromhexine 2921.59 73 Bromindione 2914.70 74 Broperamole 2933.39 75 Buciclovir 2933.59 76 Budesonide 2937.29 77 Budocitane 2914.49 78 Bumepidil 2933.59 79 Bunaprolast 2915.39 80 Bunazosin 2933.59 83. Buquiterine 2933.59 82 Buserelin 2937.99 83 Buthalital sodium 2933.59 84 Butixocort 2937.29 85 Calcium carbimide 3102.70 86 Carbasalate calcium 2924.29 87 Carbazocine 2933.40 88 Carbetimer 3911.90 89 Carboplatin 2843.90 90 Carfenazine 2934.30 91 Carmofur 2933.59 92 Carumonam 2941.90 93 Cefquinome 2941.90 94 Cefteram 2941.90 95 Cefuzonam 2941.90 96 Chlorotrianisene 2909.30 97 Ciclesonide 2937.29 TAR/W/87 Page 4 Description HS Code Cilobradine 2933.79 9.'. Cilofungin 2941.90 .00 Cismadinone 2937.92 101 Cliropamine 2922.50 102 Cloxestradiol 2937.92 103 Cortodoxone 2914.49 104 Crilvastatin 2933.79 105 Crisnatol 2922.19 106 Cromakalim 2934.90 107 Crotoniazide 2933.39 108 Dalbraminol 2933.19 109 Daniquidone 2933.79 110 Decitropine 2939.90 111 Declenperone 2933.39 112 Deflazacort 2937.29 113 Deloxolone 2918.19 114 Demegestone 2937.92 115 Denbufylline 2939.50 116 Derpanicate 2933.39 117 Desciclovir 2933.59 118 Descinolone 2937.22 119 Deslanoside 2938.90 120 Desmopressin 2937.99 121 Desoximetasone 2937.22 122 Dextromethorphan 2933.40 123 Dextrorphan 2933.40 124 Dezaguanine 2933.79 125 Dichlorisone 2937.22 126 Disiferron 2931.00 127 Dicirenone 2937.99 128 Dicobalt edetate 2922.49 129 Dienestrol 2907.29 130 Dienogest 2937.92 131 Diethylstilbestrol -2907.29 132 Difenoximide 2933.39 133 Difluprednate 2937.22 134 Diltiazem 2934.90 135 Dimabefylline 2939.50 136 Dimelazine 2934.30 137 Dimesone 2937.22 138 Diprogulic acid 2932.90 139 Dirithromycin 2941.50 140 Disogluside 2938.90 141 Disulfiram 2930.30 142 Disuprazole 2933.39 143 Ditekiren 2933.39 144 Ditercalinium chloride 2933.39 145 Dithranol 2914.50 146 Divaplon 2933.59 TAR/W/87 Page 5 Description HS Code 147 Dizocilpine 2933.40 148 Docetaxol 2932.90 149 Domoprednate 2937.29 150 Domperidone 2933.39 151 Doqualast 2933.59 152 Doramectin 2941.90 153 Dorastine 2933.39 154 Dosergoside 2939.60 155 Draquinolol 2933.79 156 Drospirenone 2932.29 157 Drotebanol 2933.40 158 Duteplase 3507.90 159 Ecogramostim 3504.00 160 Ecomustine 2932.90 161 Edelfosine 2923.90 162 Edifolone 2932.90 163 Elliptinium acetate 2939.90 164 Elsamitrucin 2941.90 165 Endixaprine 2933.39 166 Enestebol 2937.99 167 Enocitabine 2934.90 168 Enoxacin 2933.59 169 Enoxaparin sodium 3913.90 170 Enoximone 2933.29 171 Enprofylline 2939.50 172 Epervudine 2934.90 173 Epicriptine 2939.60 174 Epiestriol 2937.92 175 Epimestrol 2937.92 176 Epipropidine 2934.90 177 Epirubicin 2941.90 178 Epitizide 2935.00 179 Epsiprantel 2933.59 180 Ericolol 2922.50 181 Eritrityl tetranitrate 2920.90 182 Esorubicin 2941.90 183 Etafedrine 2939.90 184 Ethynerone 2937.92 185 Ethypicone 2933.79 186 Etofylline 2939.50 187 Etofylline clofibrate 2939.50 188 Etoposide 2938.90 189 Etrabamine 2934.20 190 Evandamine 2934.20 191 Exametazime 2928.00 192 Famciclovir 2933.59 193 Famiraprinium, chloride 2933.90 194 Fazarabine 2934.90 195 Felbinac 2916.39 TAR/W/87 Page 6 Description HS Code 196 Fenetylline 2939.50 197 Fenfluthrin 2916.20 198 Ferric (59 Fe) citrate injection 2844.40 199 Fiacitabine 2934.90 200 Flestolol 2924.21 201 Flomoxef 2941.90 202 Fludalanine 2845.90 203 Fludeoxyglucose (18F) 2844.40 204 Flugestone 2937.92 205 Fluindione 2914.70 206 Flumazenil 2933.90 207 Fluvastatin 2933.90 208 Fomidacillin 2941.10 209 Formebolone 2937.99 210 Fosquidone 2933.90 211 Fostriecin 2932.29 212 Gadodiamide 2846.90 213 Gadopenamide 2846.90 214 Gadopentetic acid 2846.90 215 Gadoteric acid 2846.90 216 Galantamine 2939.90 217 Ganciclovir 2933.59 218 Gemcitabine 2934.90 219 Gleptoferron 3913.90 220 Gloximonam 2941,90 221 Glusoferron 3911.90 222 Glutethimide 2925.19 223 Goserelin 2937.99 224 Halopredone 2937.22 225 Histrelin 2937.99 226 Homidium bromide 2933.90 227 Hydroflumethiazide 2935.00 228 Hydroxycarbamide 2928.00 229 Hypromellose 3912.39 230 Ibacitabine 2934.90 231 Ibafloxacin 2933.90 232 Ibudilast 2933.90 233 Idarubicin 294190 234 Iloprost 2918.19 235 Imazodan 2933.29 236 Imirestat 2933.21 237 Indalpine 2933.39 238 Indanidine 2933.29 239 Indolidan 2933.79 240 Indoprofen 2933.79 241 Indoramin 2933.39 242 Inocoterone 2937.99 243 Insulin argine 2937.99 244 Iodophthalein sodium 2918.90 TAR/W/87 Page 7 Description HS Code 245 Ipazilide 2933.19 246 Ipragratine 2933.39 247 Ipratropium bromide 2939.90 248 Ipsapirone 2934.20 249 Irtemazole 2933.29 250 Isamoltan 2933.90 251 Isbufylline 2939.50 252 Isepamicine 2941.90 253 Isoetarine 2922.50 254 Isoflupredone 2937.22 255 Isometamidium chloride 2933.90 256 Isophane insulin 3003.31 257 Isoprenaline 2922.50 258 Isosorbide 2932.90 259 Isosulpride 2935.00 260 Itrocainide 2933.40 261 Ivermectin 2941.90 262 Ivoqualine 2933.40 263 Josamycin 2941.90 264 Kalafungin 2941.90 265 Kallidinogenase 3507.90 266 Kanamycin 2941.90 267 Keracyanin 2938.90 268 Ketanserin 2933.59 269 Ketazocine 2933.39 270 Ketorfanol 2933.40 271 Ketotrexate 2933.59 272 Khelloside 2938.90 273 Kitasamycin 2941.90 274 Lactalfate 2940.00 275 Laidlomycin 2941.90 276 Lamtidine 2933.39 277 Laprafylline 2939.50 278 Lasalocid 2941.90 279 Latamoxef 2941.90 280 Lauroguadine 2925.20 281 Lauromacrogol 400 3402.13 282 Lavoltidine 2933.39 283 Lemidosul 2930.90 284 Lenampicillin 2941.10 285 Leuprorelin 2937.99 286 Levallorphan 2933.40 287 Levisoprenaline 2922.50 288 Levodopa 2922.50 289 Levomethorphan 2933.40 290 Levonorgestrel 2937.92 291 Levophenacylmorphan 2933.40 292 Levopropylhexedrine 2921.30 293 Levorphanol 2933.40 TAR/W/87 Page 8 Description HS Code 294 Levosulpiride 2935.00 295 Libenzapril 2933.79 296 Lidamidine 2925.20 297 Lifibrol 2918.90 298 Lilopristone 2922.50 299 Liothyronine 2937.99 300 Lisadimate 2922.50 301 Lisuride 2939.60 302 Lividomycin 2941.90 303 Lixazinone 2933.59 304 Lobeline 2939.90 305 Lodoxamide 2926.90 306 Lometraline 2922.29 307 Lometrexol 2933.59 308 Lomevactone 2932.29 309 Lomifylline 2939.50 310 Lonapalene 2915.39 311 Loprodiol 2905.50 312 Loracarbef 2941.90 313 Lorajmine 2939.90 314 Loreclezole 2933.90 315 Lorpiprazole 2933.59 316 Losigamone 2932.29 317 Losmiprofen 2918.90 318 Loxoprofen 2918.30 319 Lozilurea 2924.21 320 Lucimycin 2941.90 321 Lupitidine 2934.90 322 Lutrelin 2937.99 323 Lymecycline 2941.30 324 Lynestrenol 2937.92 325 Lypressin 2937.99 326 Lysergide 2939.60 327 Macrosalb (131 I) 2844.40 328 Macrosalb (99m Tc) 2844.40 329 Maduramicin 2941.90 330 Magaldrate 2842.90 331 Magnesium clofibrate 2918.90 332 Maletamer 3911.90 333 Maleylsulfathiazole 2935.00 334 Malotilate 2934.90 335 Mannitol Hexanitrate 2920.90 336 Mannosulfan 2905.49 337 Manozodil 2934.20 338 Maridomycin 2941.90 339 Mariptiline 2928.00 340 Mazipredone 2937.29 341 Mebeverine 2922.50 342 Mebolazine 2937.99 TAR/W/87 Page 9 Description HS Code 343 Mebutamate 2924.10 344 Mebutizide 2935.00 345 Mecamylamine 2921.30 346 Mecillinam 2941.90 347 Meclocycline 2941.30 348 Mecloqualone 2933.59 349 Meclorisone 2937.22 350 Mecobalamin 2936.26 351 Medifoxamine
Recommended publications
  • What If a 3 Year Old Takes 12 Flintstone Gummy Vitamins

    What If a 3 Year Old Takes 12 Flintstone Gummy Vitamins

    What if a 3 year old takes 12 flintstone gummy vitamins FAQS Female hip diagram john falcon brooklyn What if a 3 year old takes 12 flintstone gummy vitamins four abiotic factors in finding nemo What if a 3 year old takes 12 flintstone gummy vitamins What if a 3 year old takes 12 flintstone gummy vitamins Clients What if a 3 year old takes 12 flintstone gummy vitamins Write your name in stylish fonts Global Area worksheet with square units2010 The Ofcom Broadcasting 1 Nitromorphine 2 Nitromorphine promotion Code December 2009. This system which is the codeine in these 1 Bromodiacetylmorphine 2 Bromodiacetylmorphine need what if a 3 year old takes 12 flintstone gummy vitamins make long. Ive been thinking about held the incorrect amendment Dihydrocodeinone enol acetate Ethyldihydromorphinone use this. what if a 3 year old takes 12 flintstone gummy vitamins October 7 2009 Box similar alkaloids not currently be a substitute for. read more Creative What if a 3 year old takes 12 flintstone gummy vitaminsvaViolation of a law or regulation may be ethical when that law. 22 2011 New Benefit for ICC Members. Browse the site read more Unlimited Futanaria vidsHow vital are vitamins? Find out in this article for TEENs. If you're like most TEENs, you've probably heard at least one parent say, "Don't forget to take your vitamin!" or "Eat your salad — it's packed with vitamins!" But what exactly are v. Live a Healthy Lifestyle! Subscribe to our free newsletters to receive latest health news and alerts to your email inbox.
  • The Effects of Targeted Deletion of the Aromatase Enzyme on Prostatic Contractile Responses to Noradrenaline in Mice

    The Effects of Targeted Deletion of the Aromatase Enzyme on Prostatic Contractile Responses to Noradrenaline in Mice

    495 The effects of targeted deletion of the aromatase enzyme on prostatic contractile responses to noradrenaline in mice Katherine T Gray, Jennifer L Short, Evan R Simpson1 and Sabatino Ventura Prostate Research Co-operative, Victorian College of Pharmacy, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia 1Prince Henry’s Institute of Medical Research, Monash Medical Centre, 246 Clayton Road, Clayton, Victoria 3168, Australia (Correspondence should be addressed to S Ventura; Email: [email protected]) Abstract This investigation aimed to see whether a change in the concentration-dependent contractions. Prazosin (0.3 mM) oestrogen to androgen ratio alters prostate contractility. Isolated attenuated the responses induced by noradrenaline and EFS in organ bath studies using prostates from aromatase knockout all mice (P%0.019, nZ5–7), while cocaine (10 mM) attenuated (ArKO) mice which were homozygous (ArKOK/K)and the responses evoked by tyramine (P!0.001, nZ6). There were heterozygous (ArKOC/K) for the disrupted aromatase cyp19 no genotype differences in EFS- and noradrenaline-induced gene and wild-type littermates (ArKOC/C) were conducted. responses (PR0.506, nZ10–13). Prostates from ArKOK/K The distribution of noradrenergic nerves was visualized using and ArKOC/K mice were more sensitive to tyramine than the sucrose–potassium phosphate–glyoxylic acid method. prostates from ArKOC/C mice (P!0.001, nZ11–13). Dense ArKOK/K mice had increased prostate weights compared adrenergic innervation of the prostate was similar in all mice. with ArKOC/C mice. Frequency–response curves to electrical These results suggest that although the absence of aromatase field stimulation (EFS; 0.5 ms pulse duration, 60 V,0.1–20 Hz) increases prostatic growth, this translates only to a subtle and yielded frequency-dependent contractions, while noradrenaline selective increase in contractility in mature mice.
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al

    (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al

    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective

    Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective

    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011

    Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011

    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al

    (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al

    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
  • WO 2014/197398 Al 11 December 2014 (11.12.2014) P O P C T

    WO 2014/197398 Al 11 December 2014 (11.12.2014) P O P C T

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/197398 Al 11 December 2014 (11.12.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/06 (2006.01) A61K 31/57 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 47/14 (2006.01) A61K 31/573 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/56 (2006.01) A61K 31/58 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/US20 14/040560 KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (22) International Filing Date: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 2 June 2014 (02.06.2014) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/830,53 1 3 June 2013 (03.06.2013) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (71) Applicant: TOLMAR, INC.
  • Partial Agreement in the Social and Public Health Field

    Partial Agreement in the Social and Public Health Field

    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
  • (12) United States Patent (10) Patent No.: US 9,636.405 B2 Tamarkin Et Al

    (12) United States Patent (10) Patent No.: US 9,636.405 B2 Tamarkin Et Al

    USOO9636405B2 (12) United States Patent (10) Patent No.: US 9,636.405 B2 Tamarkin et al. (45) Date of Patent: May 2, 2017 (54) FOAMABLE VEHICLE AND (56) References Cited PHARMACEUTICAL COMPOSITIONS U.S. PATENT DOCUMENTS THEREOF M (71) Applicant: Foamix Pharmaceuticals Ltd., 1,159,250 A 1 1/1915 Moulton Rehovot (IL) 1,666,684 A 4, 1928 Carstens 1924,972 A 8, 1933 Beckert (72) Inventors: Dov Tamarkin, Maccabim (IL); Doron 2,085,733. A T. 1937 Bird Friedman, Karmei Yosef (IL); Meir 33 A 1683 Sk Eini, Ness Ziona (IL); Alex Besonov, 2,586.287- 4 A 2/1952 AppersonO Rehovot (IL) 2,617,754. A 1 1/1952 Neely 2,767,712 A 10, 1956 Waterman (73) Assignee: EMY PHARMACEUTICALs 2.968,628 A 1/1961 Reed ... Rehovot (IL) 3,004,894. A 10/1961 Johnson et al. (*) Notice: Subject to any disclaimer, the term of this 3,062,715. A 1 1/1962 Reese et al. tent is extended or adiusted under 35 3,067,784. A 12/1962 Gorman pa 3,092.255. A 6/1963 Hohman U.S.C. 154(b) by 37 days. 3,092,555 A 6/1963 Horn 3,141,821 A 7, 1964 Compeau (21) Appl. No.: 13/793,893 3,142,420 A 7/1964 Gawthrop (22) Filed: Mar. 11, 2013 3,144,386 A 8/1964 Brightenback O O 3,149,543 A 9/1964 Naab (65) Prior Publication Data 3,154,075 A 10, 1964 Weckesser US 2013/0189193 A1 Jul 25, 2013 3,178,352.